Alder BioPharma (ALDR) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Alder Biopharm (ALDR) Bullish View Reiterated at Brean Following Q2 Result and Recent Positive ALD403 Data
July 27, 2016 10:36 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $45 price target on Alder Biopharm (NASDAQ: ALDR) following Q2 results, recent data showing ALD403's durability and Phase 3 data in the 1st-half of 2017.
Aschoff commented, "Alder ended 2Q16 with cash of $450M, which should be able to support operations into 2H18. On Monday, Alder announced positive top-line 24-week data demonstrating sustained migraine... More
Alder Biopharm (ALDR) PT Bumped to $62 at Jefferies as 403 Continues To Advance
July 27, 2016 8:29 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Alder Biopharm (NASDAQ: ALDR) to $62.00 (from $61.00) as '403 continues to advance.
Abrahams commented, "ALD403 continues to advance on track, and expenses were in line with expectations. Announced... More
